Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

300%(3 trials)

Terminated

2(67%)

Phase Distribution

Ph phase_2

33%

Ph phase_1

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (66.7%)

Phase 21 (33.3%)

Trials by Status

terminated267%

completed133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_1

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

NCT02698176

completedphase_1

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

NCT02259114

terminatedphase_2

A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)

NCT02296476

Clinical Trials (3)

Showing 3 of 3 trials

NCT02698176Phase 1

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Terminated

NCT02259114Phase 1

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Completed

NCT02296476Phase 2

A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3